- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06130995
Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
Phase IB Trial of Relugolix and Enzalutamide as Neoadjuvant/ Adjuvant to Local-regional Treatment in Patients With High-risk Locally Advanced Prostate CAncer (RENAPCA)
The goal of this clinical trial is to test how effective and safe it is to use a combination of two medications, relugolix and enzalutamide, in patients with advanced prostate cancer. We want to see if this combination can help improve the chances of curing the cancer and make the patients live longer without the cancer getting worse.
The main questions we want to answer in this study are:
- Can using relugolix and enzalutamide together help increase the chances of curing high-risk advanced prostate cancer?
- Does this combination treatment help patients live longer without their cancer getting worse?
Participants in this study will be asked to take relugolix and enzalutamide as part of their cancer treatment. They will also undergo Radiation Therapy or prostatectomy, which are standard treatments for this type of cancer.
Study Overview
Status
Intervention / Treatment
Detailed Description
This clinical trial aims to assess the effectiveness and safety of combining relugolix and enzalutamide as neoadjuvant and adjuvant androgen deprivation therapy (ADT) in patients diagnosed with high-risk locally advanced prostate cancer who are also candidates for definitive radiation therapy (RT) or surgical treatment. The objectives of this phase Ib clinical trial are to evaluate the efficacy, safety, and dynamic changes in biomarkers associated with this combination therapy. A combined total of up to 41 evaluable patients will participate in this study, with the initial safety lead-in cohorts involving a potential enrollment of 12 patients, followed by a dose expansion cohort that may include up to 29 subjects.
The combined treatment cycle spans 28 days, with patients receiving six months of neoadjuvant therapy followed by an additional 18 months in the adjuvant setting. Treatment duration may be shortened if unacceptable toxicity occurs or if a patient withdraws consent. Approximately 24 months of post-accrual follow-up are anticipated to adequately assess the efficacy and safety of the treatment.
Ultimately, the study aims to contribute valuable insights into the potential benefits of neoadjuvant and adjuvant hormonal therapy with relugolix plus enzalutamide in improving outcomes for patients facing high-risk locally advanced prostate cancer.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: lead onco nurse, RN
- Phone Number: 405-271-8777
- Email: SCCIITOffice@ouhsc.edu
Study Contact Backup
- Name: Kelly Stratton, MD
- Phone Number: (405) 271-6900
- Email: Kelly-Stratton@ouhsc.edu
Study Locations
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Stephenson Cancer Center at OU Health, University of Oklahoma Health Sciences Center (SCC-OUHSC)
-
Contact:
- Kelly Stratton, MD
- Phone Number: 405-271-6900
- Email: Kelly-Stratton@ouhsc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Capable of giving signed informed consent;
- Patients must be ≥18 years of age at the time of signing the informed consent form.
Men with a diagnosis of adenocarcinoma of the prostate pathologically proven diagnosis with the following:
• Locally advanced high-risk prostate defined as i. PSA >20 ng/mL or ISUP grade 4/5 (Gleason score >7) or cT2c or ii. Any PSA, any ISUP grade, cT3-4 or cN+ (locally advanced)
Have normal organ and bone marrow function measured at the screening visit including
- Platelets ≥100 × 103/microliter (μL);
- Hemoglobin ≥ 10.0 grams/dL;
- Leukocytes (WBC) ≥ 3 × 103/μL;
- Absolute neutrophil count ≥1.5 × 103/μL;
- Serum AST and ALT ≤2.5 × upper limit of normal (ULN);
- Total bilirubin ≤1.5 ×ULN (unless values are consistent with Gilbert's syndrome for which the total bilirubin must be < 3x ULN);
- Serum creatinine ≤ 1.5 × ULN; OR Measured or calculated creatinine clearance ≥30 mL/min for participant with creatinine levels >1.5 × institutional ULN
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- The participant has, in the opinion of the investigator, a life expectancy of at least 6 months.
- Male patients must be willing to use contraception during treatment and for 3 months after the last dose of study treatment when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential.
Exclusion Criteria:
- History of major adverse cardiac event, including myocardial infarction, new congestive heart failure (CHF) or CHF exacerbation, or stroke, within the past 6 months.
- Patients who are receiving any other investigational agents.
- Patients with distant metastatic cancer will be excluded from the study as intermittent hormonal therapy is not standard of care treatment for this population.
- Active secondary malignancies requiring treatment
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to any of study drugs
- Participants with uncontrolled intercurrent illness.
- Participant is unable to swallow pills.
- Not a candidate for surgical or radiation therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prostate Cancer Combo Therapy Trial
A single-arm Phase Ib study explores the effectiveness and safety of neoadjuvant and adjuvant hormonal therapy combining relugolix and enzalutamide in high-risk locally advanced prostate cancer patients eligible for ADT followed by radiation therapy or surgery.
|
Dose level of Relugolix and Enzalutamide Safety Lead-in Cohort, 3-12 patient. Relugolix;120 mg, oral, once daily, with a loading dose of 360 mg on day 1, Enzalutamide; 120-160 mg, oral, once daily. Dose Expansion Cohort, up to 34 patients. Relugolix;120 mg, oral, once daily, with a loading dose of 360 mg on day 1, Enzalutamide; To be determined by safety lead-in cohort. One cycle = 3 months The dose limiting toxicity (DLT) period is the first 28 days Neoadjuvant ADT: 6 months; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily Concurrent ADT during Radiation Therapy; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily Maintenance ADT: Additional 18 months; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patient experiencing dose limiting toxicity (DLT) and tolerable dose of relugolix and enzalutamide combination
Time Frame: 2-3 years
|
Proportion of patients will undergo evaluation for dose-limiting toxicity (DLT) to establish a tolerable dosage regimen for the combined use of relugolix and enzalutamide in individuals diagnosed with high-risk locally advanced prostate cancer.
The assessment hinges on identifying DLTs associated with this treatment using 3-12 patients from the safety lead-in cohort and continuously monitoring treatment-related adverse events throughout the DLT observation period, which spans 24 months, encompassing neoadjuvant and adjuvant treatment phases.
|
2-3 years
|
Proportion of patients experiencing Pathologic Complete Response (pCR) and Minimal Residual Disease (MRD) in Neoadjuvant ADT with the combination of Relugolix and Enzalutamide
Time Frame: 4-6 years
|
Proportion of patients achieving a pathologic response rate, defined as the combined Pathologic Complete Response (pCR) Rate and Minimal Residual Disease (MRD) rate (MRD, tumor ≤5 mm), serves as the primary endpoint for the dose expansion cohort.
This assessment will be conducted using Simon's optimal 2-stage design, enabling a determination of whether there are an adequate number of patients with objective responses to proceed to the second stage of the study (at the interim analysis) or to consider the drug for further investigation in a Phase III study (at the study's conclusion).
|
4-6 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR) of neoadjuvant ADT of relugolix and enzalutamide
Time Frame: 4-6 years
|
Assessing the objective response rate (ORR) in patients with high-risk locally advanced prostate cancer eligible for definitive radiation therapy (RT) or radical prostatectomy, following neoadjuvant ADT with relugolix and enzalutamide.
ORR will be determined based on MRI imaging confirmation, defined as the percentage of patients achieving a complete response (CR) or partial response (PR) per RECIST v1.1 criteria.
|
4-6 years
|
Frequency and severity of adverse events of relugolix and enzalutamide
Time Frame: 4 years
|
Assessment includes the rate and severity of treatment-related adverse events as per the NCI CTCAE v5 grading system.
|
4 years
|
Prostate specific antigen (PSA) response to the combination of relugolix and enzalutamide
Time Frame: 4 years
|
Measurement of prostate-specific antigen (PSA) response, includes the rate and duration of a 50% reduction in PSA levels from baseline.
|
4 years
|
Diagnostic precision and constraints of biopsy in assessing positive margin rates and rates of pathologic downgrade.
Time Frame: 4-6 years
|
Assessments involves diagnostic capabilities of biopsy-based analysis for prostatectomy, as reflected in the rates of positive margin in whole-mount pathology following intense neoadjuvant therapy and the pathologic downgrade compared to the initial T stage.
|
4-6 years
|
Progression-Free Survival (PFS) in Patients Receiving Neoadjuvant Relugolix and Enzalutamide
Time Frame: 4-6 years
|
Assessment of Progression-Free Survival (PFS); defined as the interval from the initial dose to the earliest evaluation of progression according to RECIST v1.1 criteria, in patients undergoing neoadjuvant treatment with Relugolix and Enzalutamide, followed by radical local-regional Radiation Therapy (RT) or Radical Prostatectomy (RP) and subsequent adjuvant maintenance Androgen Deprivation Therapy (ADT).
|
4-6 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Androgen Antagonists
- Relugolix
Other Study ID Numbers
- OU-SCC-RENAPCA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Androgen Deprivation Therapy
-
Herlev HospitalCompletedProstatic Neoplasms | Androgen Deprivation Therapy | Exercise TherapyDenmark
-
Institut Mutualiste MontsourisUniversity of Turin, ItalyRecruitingProstate Cancer | Androgen Deprivation TherapyFrance
-
Azienda Unità Sanitaria Locale Reggio EmiliaUniversity of Modena and Reggio Emilia; Fondazione Manodori di Reggio EmiliaCompletedProstate Cancer | Radiotherapy | Androgen Deprivation TherapyItaly
-
Norwegian School of Sport SciencesKing's College London; Oslo University Hospital; Rigshospitalet, Denmark; University... and other collaboratorsTerminatedProstate Cancer | Resistance Exercise | Androgen Deprivation TherapyNorway
-
UNC Lineberger Comprehensive Cancer CenterWake Forest University Health SciencesCompletedCastration-resistant Prostate Cancer | Androgen Deprivation TherapyUnited States
-
Associacao de Investigacao de Cuidados de Suporte...Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.; University Institute... and other collaboratorsUnknownProstate Cancer | Androgen Deprivation TherapyPortugal
-
University of CopenhagenNovo Nordisk A/S; Danish Cancer Society; TrygFonden, Denmark; Beckett FoundationCompletedHealth Effects of Soccer Training in Men With Prostate Cancer Receiving Androgen Deprivation TherapyProstatic Neoplasms | Exercise | Androgen Deprivation Therapy | Soccer TrainingDenmark
-
University of Colorado, DenverRecruitingHypertension | Prostate Cancer | Autonomic Dysfunction | Androgen Deprivation Therapy | Renal DiseaseUnited States
-
Odense University HospitalZealand University HospitalUnknownProstate Cancer | Osteoporosis | Androgen Deprivation TherapyDenmark
-
Dana-Farber Cancer InstitutePfizer; Prostate Cancer FoundationRecruitingProstate Cancer | Prostate Cancer Metastatic | Androgen Deprivation TherapyUnited States
Clinical Trials on Relugolix and Enzalutamide
-
Yale UniversityPfizerRecruiting
-
ESSA PharmaceuticalsRecruitingProstate CancerCanada, United States, Australia
-
TakedaCompleted
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedProstate Cancer | Pharmacokinetics of EnzalutamideUnited States
-
National Cancer Institute (NCI)Terminated
-
Radboud University Medical CenterActive, not recruitingProstatic Neoplasms, Castration-ResistantNetherlands
-
Groupe Hospitalier Pitie-SalpetriereCompletedEpilepsy | Prostate Cancer | Neuropathy | EncephalopathyFrance
-
Sumitomo Pharma Switzerland GmbHActive, not recruiting
-
Translational Research Center for Medical Innovation...Kagawa UniversityCompleted
-
Andreas JosefssonGöteborg University; Umeå University; Sahlgrenska University Hospital, Sweden; Sundsvall... and other collaboratorsTerminated